Skin permeating and cell entering (SPACE) peptides and methods of use thereof

Apply for Patent – Protect your earth-moving ideas with PowerPatent software service for Online Patent Application

The The Regents Of The University Of California patent solves the following problem:

Skin, the largest organ in the human body, is a company of many dermatological diseases that collectively represent a large category of human health. Therefore, successful delivery of therapeutics, eg, macromolecules such as siRNA, into the skin may be a topic of active research and development. The goal of topical siRNA delivery, however, is very difficult and with few exceptions, very difficult to do. The first challenge was poor skin penetration of macromolecules. Among the various methods of physico-chemical proposed to improve the penetration of macromolecules, peptide carriers that have emerged as potential candidates for their simplicity of use, diversity and potential ability to target cellular sub-types in the skin. Several peptides including tat, polyarginine, meganin, and penetratin, recognized for the delivery of drugs into the cytoplasm of the cell, which tested the penetration across the stratum corneum (SC) and some showed some effective delivery of small molecules to the skin. In contrast, only one peptide, TD-1, specifically shown to penetrate the SC and possess the ability to enhance the systemic uptake of topically applied drugs. Although some peptide known to penetrate cellular membranes and some penetrate the SC, the peptide would simultaneously improve the penetration of macromolecules and other actives across the SC and / or over the cellular membranes of live, can skin and dermal cells needed.

Our analysis of this patent is as follows:

The Regents Of The University Of California’s patent US 8791062 B2 deals with Skin permeating and cell entering (SPACE) peptides and methods of use thereof.
The present disclosure provides peptide and peptide compositions, which facilitate the delivery of an active agent or an active agent carrier, wherein the composition is capable of penetrating the stratum corneum (SC) / or the cellular membranes of viable cells.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Compositions and methods for modulating vascular development

Use PowerPatent’s Online Patent Filing Service to get quick patent protection for your great idea.

The Genentech Inc. patent solves the following problem:

Development of a vascular supply is a fundamental requirement for many physiological and pathological processes. Actively growing tissues such as embryos and tumors require adequate blood supply. They satisfy this need by bringing in pro-angiogenic factors, which promote new blood vessel formation by a process called angiogenesis. Vascular tube formation is a complex but orderly biological event involving all or many of the following steps: a) endothelial cells (ECs) proliferate from the current evacuation center or the difference from the ancestor cells; b) ECs migrate and coalesce to form cord-like structures; c) vascular cords then pass tubulogenesis to form vessels with a central lumen d) existing cords or vessels send sprouts to form secondary vessels; e) primitive vascular plexus undergo further remodeling and reshaping; and f) peri-endothelial cells are recruited within the endothelial tubes, providing maintenance and modulatory functions to the vessels; such cells including pericytes for small capillaries, smooth muscle cells for larger vessels, and myocardial cells in the heart. Hanahan, D. Science 277: 48-50 (1997); Hogan, BL & Kolodziej, PA Nature Reviews Genetics. 3: 513-23 (2002); Lubarsky, B. & Krasnow, MA Cell. 112: 19-28 (2003).

Our analysis of this patent is as follows:

Genentech Inc.’s patent US 8790646 B2 deals with Compositions and methods for modulating vascular development.
The present invention provides methods of using EGFL7 enemy again in vascular development. Also here are the ways of screening for modulators of EGFL7 activity. Furthermore, methods of treatment using EGFL7 enemy given.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Treatment of vasculoproliferative conditions with Lrg1 anatgonists

You’ve invested time, talent, and energy into making a dent in the universe with your invention and ideas. Now it’s time to make sure it’s protected with PowerPatent’s Utility, Provisional or Design Patent Filing Software

The Ucl Business Plc patent solves the following problem:

Aberrant remodeling of retinal vasculature is a prominent part of the sight-threatening conditions such as diabetic retinopathy, retinal vein occlusion, retinopathy of prematurity, age-related macular degeneration and macular telangiectasia. These vascular changes manifest themselves as two of the new capillary growth from pre-existing retinal vessels (angiogenesis) and the development of vascular malformations of existing vessels (telangiectasia example). This pathogenic vascular remodeling in these diseases are a major cause of loss of vision.

Our analysis of this patent is as follows:

Ucl Business Plc’s patent US 8790647 B2 deals with Treatment of vasculoproliferative conditions with Lrg1 anatgonists.
This invention relates to the field of molecular physiology. In particular, this invention relates to the treatment of vasculoproliferative conditions, especially in the eyes and in the treatment of tumors that show vascular proliferation. Levels of leucine-rich alpha-2-glycoprotein (Lrg1) are shown to be increased in patients who suffer from these conditions and animal models such circumstances. Antagonist Lrg1 be used to treat vasculoproliferative circumstances.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Pharmaceutical composition comprising a bispecific antibody for EpCAM

You’ve invested time, talent, and energy into making a dent in the universe with your invention and ideas. Now it’s time to make sure it’s protected with PowerPatent’s Utility, Provisional or Design Patent Filing Software

The Amgen Research (Munich) Gmbh patent solves the following problem:

Our analysis of this patent is as follows:

Amgen Research (Munich) Gmbh’s patent US 8790645 B2 deals with Pharmaceutical composition comprising a bispecific antibody for EpCAM.
The present invention provides a pharmaceutical composition comprising a bispecific chain antibody making. Said bispecific chain antibody conduct described in containing or comprising at least two domains, where one of said at least two domains specifically binds to human EpCAM and comprises at least one CDR-H3 regions containing amino acid is NXID antigen and a second domain binds the human CD3 antigen. the invention further provides a process for the production of the pharmaceutical composition of the invention, a method for the prevention, treatment or Amelioration of a tumor disease and the use of expressed bispecific chain antibody making and equal means of prevention, treatment or Amelioration of a tumor disease.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Production of high mannose proteins in plant culture and therapeutic uses thereof

Use PowerPatent’s Online Patent Filing Service to get quick patent protection for your great idea.

The Protalix Ltd. patent solves the following problem:

Gaucher's disease is the most prevalent lysosomal storage disorder. This is due to an observed gene disorder (chromosome 1 q21 Q31) that resulted in the glucocerebrosidase deficiency, also known as glucosylceramidase, which is a membrane-bound lysosomal enzyme that catalyzes the hydrolysis of glycosphingolipid glucocerebroside (glucosylceramide GlcCer) to glucose and ceramide. Gaucher disease is caused by point mutations in hGCD (human glucocerebrosidase) gene (GBA), resulting in the accumulation of GlcCer the lysosomes of macrophage. The nature of storage cells, called Gaucher cells, found in liver, spleen and bone marrow. The associated clinical symptoms include severe hepatosplenomegaly, anemia, thrombocytopenia and skeletal deterioration.

Our analysis of this patent is as follows:

Protalix Ltd.’s patent US 8790641 B2 deals with Production of high mannose proteins in plant culture and therapeutic uses thereof.
A device, system and method for the production of glycosylated proteins in plant culture, especially proteins with a high mannose glycosylation, while targeting these proteins in an ER signal and / or through the Golgi. invention further relates to vectors and methods for the expression and production of enzymatically active high mannose lysosomal enzymes using transgenic plant root, particularly carrot cells. Particularly, the invention relates to host cells, particularly transgenic suspended carrot cells, vector and methods for high yield expression and production of biologically active high mannose Glucocerebrosidase (GCD). invention further provides for compositions and methods for the treatment of lysosomal storage diseases.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Desaturases and methods of using them for synthesis of polyunsaturated fatty acids

Protect your invention by filing a Provisional or Utility Patent Application using our software today! It’s easy and fully backed by patent lawyers – and you don’t have to pay until you’re done.

The Washington State University Research Foundation patent solves the following problem:

Fatty acids are important components of living systems. They are a major part of the cytoplasmic membranes, common in plants, animals and protists alike.

Our analysis of this patent is as follows:

Washington State University Research Foundation’s patent US 8791327 B2 deals with Desaturases and methods of using them for synthesis of polyunsaturated fatty acids.
The amino acid and nucleic acid sequences in a 5-desaturase enzyme and an 8-desaturase enzyme expressed. The nucleic acid sequences can be used to design artificial DNA constructs and vectors. These vector then be used to change various organisms, including for example, plants and yeast. The transformed organisms and polyunsaturated fatty acids. The amino acid sequences are useful for creating enzyme-specific antibodies useful for identifying the desaturases.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Selective high frequency spinal cord modulation for inhibiting pain with reduced side effects, and associated systems and methods

Use PowerPatent’s Online Patent Filing Service to get quick patent protection for your great idea.

The Nevro Corporation patent solves the following problem:

Neurological stimulators developed to treat pain, movement disorders, functional disorders, spasticity, cancer, heart disorders, and various medical conditions. Implantable neurological stimulation system usually has an Implantable pulse generator and one or more leads that deliver electrical pulses to the nervous system tissue or muscle tissue. For example, certain neurological stimulation system for spinal cord stimulation (SCs) have cylindrical heads that includes a lead body with a circular cross-sectional shape and one or more conductive rings spaced apart from each one at the distal end of the lead body. The conductive rings operate as individual electrodes and, in many cases, the SCs leads implanted percutaneously through a large needle is inserted into the epidural space, or without the aid of a stylet.

Our analysis of this patent is as follows:

Nevro Corporation’s patent US 8792988 B2 deals with Selective high frequency spinal cord modulation for inhibiting pain with reduced side effects, and associated systems and methods.
Selective high-frequency spinal cord modulation in inhibiting pain with reduced side effects and related systems and methods are disclosed. In particular embodiments, the high-frequency modulation range from 1.5 kHz to 50 kHz can be applied to the patient's spinal cord region in response to lower back pain without creating unwanted sensory and / or motor side in effect. In other embodiments, modulation according to the same parameters can be applied to other lines or peripheral areas to address other signs.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Positioning graphical objects within previously formatted text

You’ve invested time, talent, and energy into making a dent in the universe with your invention and ideas. Now it’s time to make sure it’s protected with a PowerPatent Utility, Provisional or Design Patent Application

The Konica Minolta Laboratory U.S.A., Inc. patent solves the following problem:

An electronic document (ED) may include any number of text streams and any number of graphical objects (ie, animals, photos, drawings, etc.). The ED may also include an anchor for positioning one or more graphical objects. In particular, each anchor corresponding to a graphical object and every reason to anchor position (ie, eviction) on his watch things his own relatives. Anchor can be specified before, after, or within the text stream, like the characters of text, the anchor position on a page during a translation of ED. But, unlike the characters of text, anchors often not visible to the reader in the ED and the text and / or graphics can be placed on the anchor. Once an anchor is placed in the position to see things the anchor will be calculated based on the displacement specified anchor. It is the responsibility of a mechanical layout of a Page Translation Device (PRD) or user machine Layout text streams, anchors, and see things on the page specified in ED.

Our analysis of this patent is as follows:

Konica Minolta Laboratory U.S.A., Inc.’s patent US 8793572 B2 deals with Positioning graphical objects within previously formatted text.
A method for providing a page, including: earn an electronic document containing a text stream and an anchor worth a watch things and specifying a first eviction to see things relative to anchor; placing text streams in a region of pages; recognition on a first side of the page corresponding to anchor; calculated on a place on the page for the installation to see things; marking the watch things like pinned; start a second page layout; put in streams of text on the page by wrapping a part of the text stream around the place; recognition on a second side of the page corresponding to anchor, where the second position and place separated by a second evacuation from the first evacuation; and outputting the page with at least part of the text stream and watch things that occupy that place.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Gastric retentive extended release pharmaceutical compositions

Apply for Patent – Protect your earth-moving ideas with PowerPatent software service for Online Patent Application

The Mallinckrodt Llc patent solves the following problem:

Oral drug administration remains the route of choice for the majority of clinical applications. Extended release (ER) dosage form is administered once or twice daily offer advantages in their immediate release (IRI) counterparts because they reduce the size of the peaks and troughs in drug plasma concentration, giving dosing intervals, continuous analgesic effect, and increased patient compliance. For certain types of patients, such as those suffering from pain, these ER products allow the patient to sleep through the night without having to wake up during the night to take the next dose. Therefore, ER dosage forms which can significantly increase the quality of life for these patients. Both IRI and ER products for pain is widely available on the market. There is, however, no opioid / acetaminophen combination ER products available on the market.

Our analysis of this patent is as follows:

Mallinckrodt Llc’s patent US 8790694 B2 deals with Gastric retentive extended release pharmaceutical compositions.
The present disclosure provides high release pharmaceutical composition comprising an opioid and an additional active pharmaceutical ingredient, which compositions demonstrate gastric retentive properties to achieve a combination of physical properties the composition and release the opioid, which upon administration to a subject, the composition has at least one pharmacokinetic parameter race in less than 30% when the subject is in a fasting state compared to a fed state.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Method for the construction of vertical power transistors with differing powers by combination of pre-defined part pieces

Use PowerPatent’s Online Patent Filing Service to get quick patent protection for your great idea.

The X-Fab Semiconductor Foundries Ag, , Alpha Microelectronics Gmbh patent solves the following problem:

A vertical transistor used in the field of power electronics often contain a plurality of transistor cells arranged in a similar way and a contact terminal for the gate electrode, that is for example described in US Pat. No. 5,844,277, cf. Fig. 2The D and figs. 5-7, and US Pat. No. 5,763,914. These transistor cells have a common gate electrode, a common drain terminal at the back of the silicon wafer and a different source or terminal in silicon, however, connected in parallel with a common metal electrode. The number and size of the single transistor cells to determine the transistor, the channel width and the opposition, as described in Baliga in Power Semiconductor Devices, 1995, pages 367 forward. To obtain the necessary resistance to a vertical DMOS transistor with conventional techniques the entire transistor including a corresponding active region and an edge structure connectable periphery designed. Starting from a transistor having a first offense to obtain a second transistor with a different on-resistance it is necessary that the new design of the transistor. Often, the required electric parameters of the vertical DMOS transistor measured and described separately for each different transistor.

Our analysis of this patent is as follows:

X-Fab Semiconductor Foundries Ag, , Alpha Microelectronics Gmbh’s patent US 8793116 B2 deals with Method for the construction of vertical power transistors with differing powers by combination of pre-defined part pieces.
A method for designing a first vertical MOS power transistor with a specified design power level. method comprising the steps of forming a layout of vertical MOS power transistor as a combination of at least a portion of every Layout pieces of each of the pieces of known design data, the portion of the particle including at least a first piece of layout consisting of a given number of single transistor cells, and adjust the design specified in the power level of the first vertical mos power transistor by using the known data in the design of base part and Layout combination of parts.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.